#United States #Cambridge #Biopharmaceutical #Convergent Therapeutics #Barbara Duncan

Convergent Therapeutics Strengthens Board with New Appointment of Barbara Duncan

Convergent Therapeutics Inc., based in Cambridge, Massachusetts, announces the strategic appointment of Barbara Duncan to its Board of Directors. This move aims to bolster the company's leadership as it focuses on developing innovative radiopharmaceutical therapies aimed at addressing prostate cancer and other malignancies.

Barbara Duncan is recognized for her substantial experience in the biopharmaceutical landscape, particularly in corporate finance and business strategy. As she joins Convergent's Board, which will now encompass seven directors, her insights are expected to play a pivotal role during a critical phase of the company's development.

Philip Kantoff, MD, co-founder and CEO of Convergent Therapeutics, acknowledged Ms. Duncan's vast expertise, stating, "Barbara is a welcome addition to our Board of Directors, bringing deep experience in biopharmaceutical leadership. We are confident that she will be an important asset to the Board as we continue to drive our pipeline through clinical development."

Ms. Duncan's previous roles include serving as the Chief Financial Officer at Intercept Pharmaceuticals from 2009 until June 2016, and earlier at DOV Pharmaceutical, where she held multiple leadership titles, including Chief Executive Officer and Board Member. Her breadth of experience is critical as Convergent Therapeutics is on the cusp of advancing its lead therapeutic candidate, CONV01-α, into more extensive clinical trials.

Expressing her enthusiasm for the new role, Duncan stated, "I’m thrilled to join the Convergent Board as the company continues to unlock the full potential of alpha radioantibodies. I look forward to sharing my insights with my fellow Board members and the Convergent leadership team to progress CONV01-α as a potential next-generation cancer treatment for patients with prostate cancer."

Ms. Duncan's extensive engagement with other relevant companies underscores her commitment and influence in the biopharmaceutical sector. She holds board positions with several publicly traded biopharmaceutical firms, including Atea Pharmaceuticals, Halozyme Therapeutics, and Ovid Therapeutics. Furthermore, she has prior experience as the chairperson of Fusion Pharmaceuticals until its acquisition by AstraZeneca.

About CONV01-α

CONV01-α is an innovative radioantibody developed by Convergent Therapeutics. It merges precise antibody targeting with the destructive prowess of alpha-emitting radionuclides. By utilizing a humanized monoclonal antibody that targets the prostate-specific membrane antigen (PSMA), which is prominent in prostate cancer cells, CONV01-α aims to provide potent and localized treatment while minimizing damage to surrounding healthy tissues. The antitumor capabilities of its encapsulated Ac-225 radionuclide complement its design, providing targeted radiation specifically to cancer cells.

About Convergent Therapeutics, Inc.

Convergent Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to advancing cancer therapies utilizing radioantibody technology. Founded by a team of renowned experts in oncology and drug development, the company leverages its proprietary platform, licensed from Cornell University, to create treatments that specifically target cancer cells. This innovative approach combines the selectivity of antibodies with the powerful effects of alpha radioisotopes, offering promising solutions for cancer treatment. For further information about their initiatives, visit www.convergentrx.com and follow Convergent on social media platforms like Twitter and LinkedIn.